Document is current

Article History

Received: 29 June 2024

Accepted: 12 August 2024

First Online: 16 September 2024

Declarations

:

: Philip J. Mease: Has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galapagos, Gilead, GSK, Janssen, Moonlake Pharma, Novartis, Pfizer, Sun Pharma, Takeda, UCB Pharma, and Ventyx; speakers bureau fees from AbbVie, Amgen, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma; Andrew Blauvelt: Has served as a speaker (received honoraria) for Eli Lilly and Company and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant Sciences, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Merck, Microbion, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant Sciences, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx, and owns stock in Lipidio and Oruka; Adam P. Sima, Marie Gurrola: Employees of CorEvitas, LLC; Silky W. Beaty: Employee at the time of the study and current shareholder of UCB Pharma; Robert Low, Braulio Gomez: Employees and shareholders of UCB Pharma; Mark G. Lebwohl: Employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly and Company, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB Pharma; consultant for Almirall, AltruBio Inc., AnaptysBio, Arcutis Inc., Arena Pharmaceuticals, Aristea Therapeutics, AstraZeneca, Avotres, BioMX, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, LLC, Dermavant Sciences, EPI, Evommune Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Hexima Ltd, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, Strata, SUN Pharma, Trevi, Verrica, and Vial. Mark G. Lebwohl is an Editorial Board member of <i>Dermatology and Therapy</i>. Mark G. Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This study was performed in accordance with the Declaration of Helsinki [] and the Guidelines for Good Pharmacoepidemiology Practice []. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), (Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, before the site’s participation and initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization before participating.